Astana Biomed Group, an authorized Abcam distributor in Central Asia

Anti-IMP3 antibody [EPR12021] - BSA and Azide free (ab249982)

Key features and details

  • Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
  • Rabbit monoclonal [EPR12021] to IMP3 - BSA and Azide free
  • Suitable for: ICC, Flow Cyt, IP, WB
  • Knockout validated
  • Reacts with: Mouse, Rat, Human

Overview

  • Product name

    Anti-IMP3 antibody [EPR12021] - BSA and Azide free
    See all IMP3 primary antibodies

  • Description

    Rabbit monoclonal [EPR12021] to IMP3 - BSA and Azide free

  • Host species

    Rabbit

  • Tested applications

    Suitable for: ICC, Flow Cyt, IP, WBmore details
    Unsuitable for: IHC-P

  • Species reactivity

    Reacts with: Mouse, Rat, Human

  • Immunogen

    Recombinant fragment within Human IMP3. The exact sequence is proprietary.
    Database link: O00425

  • General notes

    Ab249982 is the carrier-free version of ab177477. This format is designed for use in antibody labeling, including fluorochromes, metal isotopes, oligonucleotides, enzymes.

     

    Our carrier-free formats are supplied in a buffer free of BSA, sodium azide and glycerol for higher conjugation efficiency.

    Use our conjugation kits  for antibody conjugates that are ready-to-use in as little as 20 minutes with

    ab249982 is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm.

    Maxpar® is a trademark of Fluidigm Canada Inc.

    This product is a recombinant monoclonal antibody, which offers several advantages including:

    • - High batch-to-batch consistency and reproducibility
    • - Improved sensitivity and specificity
    • - Long-term security of supply
    • - Animal-free production
    For more information see here.

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

    Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.

    Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.

    We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.

    In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.

    We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.

    Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.

    Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.

Properties

Images

  • Western blot - Anti-IMP3 antibody [EPR12021] - BSA and Azide free (ab249982)
    Western blot - Anti-IMP3 antibody [EPR12021] - BSA and Azide free (ab249982)

    This data was developed using ab177477, the same antibody clone in a different buffer formulation.

    Lane 1: Wild-type HAP1 whole cell lysate (20 µg)

    Lane 2: IGF2BP3 (IMP3) knockout HAP1 whole cell lysate (20 µg)

    Lane 3: HeLa whole cell lysate (20 µg)

    Lane 4: HEK293 whole cell lysate (20 µg)

    Lanes 1 - 4: Merged signal (red and green). Green - ab177477 observed at 70 kDa. Red - loading control, ab9484, observed at 37 kDa.

    ab177477 was shown to specifically react with IGF2BP3 (IMP3) in wild-type HAP1 cells along with additional cross-reactive bands. No band was observed when IGF2BP3 (IMP3) knockout cells were examined. Wild-type and IGF2BP3 (IMP3) knockout samples were subjected to SDS-PAGE. ab177477 and ab9484 (Mouse anti GAPDH loading control) were incubated overnight at 4°C at 1/1000 dilution and 1/20,000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (ab216776) secondary antibodies at 1/20,000 dilution for 1 hour at room temperature before imaging.

  • Immunocytochemistry - Anti-IMP3 antibody [EPR12021] - BSA and Azide free (ab249982)
    Immunocytochemistry - Anti-IMP3 antibody [EPR12021] - BSA and Azide free (ab249982)
    This data was developed using ab177477, the same antibody clone in a different buffer formulation.Immunofluorescent analysis of BxPC-3 cells labeling IMP3 with ab177477 at 1/50 (green) and DAPI staining (blue).
  • Flow Cytometry - Anti-IMP3 antibody [EPR12021] - BSA and Azide free (ab249982)
    Flow Cytometry - Anti-IMP3 antibody [EPR12021] - BSA and Azide free (ab249982)
    This data was developed using ab177477, the same antibody clone in a different buffer formulation.Flow cytometry analysis of BxPC-3 (human pancreas adenocarcinoma) cells labeling with purified ab177477 at 1/300 dilution ( 10ug/ml) (Red). Cells were fixed with 80% methanol and permeabilised with 0.1% Tween-20. A Goat anti rabbit IgG (Alexa Fluor® 488)(ab150077) )(1/2000 dilution) was used as the secondary antibody. Rabbit monoclonal IgG (Black)(ab172730) was used as a isotype control.Cell without incubation with primary antibody and secondary antibody (Blue) were used as unlabeled control.
  • Western blot - Anti-IMP3 antibody [EPR12021] - BSA and Azide free (ab249982)
    Western blot - Anti-IMP3 antibody [EPR12021] - BSA and Azide free (ab249982)
    All lanes : Anti-IMP3 antibody [EPR12021] (ab177477) at 1/1000 dilution

    Lane 1 : HeLa cell lysate
    Lane 2 : BxPC-3 cell lysate
    Lane 3 : 293T (Human embryonic kidney epithelial cell) cell lysate

    Lysates/proteins at 10 µg per lane.

    Secondary
    All lanes : HRP labeled goat anti-rabbit at 1/2000 dilution

    Predicted band size: 63 kDa



    This data was developed using ab177477, the same antibody clone in a different buffer formulation.

  • Immunoprecipitation - Anti-IMP3 antibody [EPR12021] - BSA and Azide free (ab249982)
    Immunoprecipitation - Anti-IMP3 antibody [EPR12021] - BSA and Azide free (ab249982)
    This data was developed using ab177477, the same antibody clone in a different buffer formulation.Immunoprecipitation of IMP3 from 293T cell lysate using ab177477 at 1/10.
  • Western blot - Anti-IMP3 antibody [EPR12021] - BSA and Azide free (ab249982)
    Western blot - Anti-IMP3 antibody [EPR12021] - BSA and Azide free (ab249982)
    All lanes : Anti-IMP3 antibody [EPR12021] (ab177477) at 1/20000 dilution

    Lane 1 : MDA-MB-231 (human breast adenocarcinoma) whole cell lysate
    Lane 2 : MDA-MB-435S (human melanoma) whole cell lysate
    Lane 3 : MCF-7 (human breast adenocarcinoma) whole cell lysate
    Lane 4 : Human Fetal Kidney

    Lysates/proteins at 20 µg per lane.

    Secondary
    All lanes : Goat Anti-Rabbit IgG H&L (HRP) at 1/2000 dilution

    Predicted band size: 63 kDa
    Observed band size: 69 kDa
    why is the actual band size different from the predicted?



    This data was developed using ab177477, the same antibody clone in a different buffer formulation.

    Blocking and dilution buffer: 5% NFDM/TBST.

    Exposure time: Lane 1: 10 seconds; Lanes 2-4: 5 seconds.

    The protein expression of IMP-3 in MCF-7 cells is negative or undetectable (PMID: 22266872).

  • Anti-IMP3 antibody [EPR12021] - BSA and Azide free (ab249982)
    Anti-IMP3 antibody [EPR12021] - BSA and Azide free (ab249982)

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Clear all

Recently viewed products

© 2021 Astana Biomed Group LLP. All rights reserved.